MANNEDORF, SWITZERLAND, and STOCKHOLM, SWEDEN--(Marketwire - January 12, 2011) - The Tecan
Group (SWISS: TECN) and Attana AB today announced that they have
signed an exclusive distributor agreement under which Tecan will distribute
Attana's biosensor instruments and assay technology in North America. The
agreement covers the Attana 100, 200 and Cell 200 instruments along with
biosensors and accompanying assay reagents as well as service and support.
The
distribution agreement leverages Tecan's sales, service and applications
capabilities in North America with Attana's biosensor technology that
allows
in-depth analyses of molecular interactions in a wide variety of research
applications.
Thomas Bachmann, CEO of Tecan, said: "We are delighted that we have been
able to
partner with Attana on such an exciting label free biosensor detection
technology. This agreement allows us to offer our North American customers
another dimension of information in their scientific disciplines. It is
part of
our strategy to leverage our own sales organization for innovative third
party
products that complement the broad product portfolio of our Life Sciences
Business."
"We are pleased to have reached an agreement with such a well established
and
innovative company", says Teodor Aastrup, CEO and founder of Attana. "We
are
confident that this collaboration will be beneficiary to the
biopharmaceutical
and academic society as a more comprehensive product portfolio will be
offered
to both Tecan's and Attana's customers. Tecan has a strong position on the
North
American market and will reach even further with Attana's biosensor
technologies."
Tecan and Attana will be officially launching their collaboration today at
the
CHI-PepTalk Conference in San Diego, USA.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and
solutions in biopharmaceuticals, forensics, and clinical diagnostics. The
company specializes in the development, production and distribution of
instruments and automated workflow solutions for laboratories in the life
sciences sector. Its clients include pharmaceutical and biotechnology
companies,
university research departments, forensic and diagnostic laboratories. As
an
original equipment manufacturer, Tecan is also a leader in developing and
manufacturing OEM instruments and components that are then distributed by
partner companies. Founded in Switzerland in 1980, the company has
manufacturing, research and development sites in both Europe and North
America
and maintains a sales and service network in 52 countries. In 2009, Tecan
generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million).
Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK:
TECN/Reuters: TECZn.S/ ISIN CH0012100191).
About Attana AB
Founded in 2002, based in Stockholm, Sweden, Attana AB develops biosensors
for
the pharmaceutical, diagnostic and academic society worldwide. With a
strong
focus on characterizing molecular interactions exactly as they occur in the
human body, Attana is committed to increasing the success during clinical
trials
by providing the life science community with biologically relevant
information.
Attana's biosensors can be used to determine specificity, kinetics and
affinity,
amongst other binding characteristics of biomolecules and macrostructures
of
varying species such as cells, antibodies, proteins, viruses and bacteria.
Tecan Group AG
Seestrasse 103 Männedorf Switzerland
ISIN: CH0012100191;
Press Release (PDF):
http://hugin.info/100384/R/1478415/414912.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE
[HUG#1478415]
